Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Hoos Discusses Patients Eligible to Receive Ipilimumab

August 3rd 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses Which Patients are Eligible to Receive Ipilimumab

Researchers Identify Gene Involved in DNA Repair From UVB Damage

July 29th 2011

The tumor suppressor gene PTEN has been linked to the removal of DNA damage from UVB radiation, a major risk factor in the development of skin cancer.

Dr. Hoos on the Ipilimumab Plus Dacarbazine Trial

July 29th 2011

Dr. Axel Hoos medical lead at bristol-myers squibb on the Ipilimumab Plus Dacarbazine Combination Trial

Flip Flops, Baseball Caps, and Skin Cancer

July 27th 2011

Sun exposure to usually-covered skin is yet another risk for skin cancer.

Dr. Hoos on Why Melanoma is Amenable to Immunotherapy

July 26th 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy

BRIM-2 Upholds Benefits Emerging with Vemurafenib in Melanoma

July 25th 2011

In patients with metastatic melanoma, the BRAF inhibitor vemurafenib led to high objective response rates and durable treatment responses.

Genomic Chaos

July 22nd 2011

Oncologists need to prepare for a new era in which rapidly advancing genetic technology will change the way cancer is treated.

Dr. Vogelzang Discusses the Cabozantinib Trial Design

July 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Dana Monroe on Yervoy Side Effect Nurse Self-Education

July 19th 2011

Dana Monroe from San Francisco Oncology Associates on Yervoy Side Effects and How Oncology Nurses Can Self-Educate

Dr. Hoos Explains the Future of Immunotherapy

July 18th 2011

Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role

Game-Changers: 11 Key Abstracts in ASCO Lineup

July 18th 2011

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Dr. Schuchter on the Progression of Melanoma Care

July 15th 2011

Dr. Lynn M. Schuchter from Penn Medicine on the Progression of Melanoma Care over the past 25 years

Dr. Schuchter on Managing Ipilimumab's Side Effects

July 13th 2011

Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program

Dr. Hoos Describes Ipilimumab and Future Immunotherapies

July 13th 2011

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Tim Turnham on the Melanoma Research Foundation

July 12th 2011

Dr. Tim Turnham the executive director of the melanoma research foundation Describes the organization

Dr. Hoos on Tools Available to Measure Ipilimumab's Success

July 7th 2011

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success

Dr. Schuchter on the Next Steps in Melanoma Research

July 7th 2011

Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research

Dr. Schuchter Limits BRAF Testing to Advanced Melanoma

June 30th 2011

Dr. Lynn Schuchter chief of Hematology Oncology at Penn Medicine Reserves BRAF Testing for Advanced Melanoma

Dr. Schuchter on Testing for a BRAF Mutation in Melanoma

June 27th 2011

Dr. Schuchter chief of Hematology Oncology at Penn Medicine on Testing for a BRAF Mutation in Melanoma

FDA Roundup, Including Latest on Avastin Hearing

June 24th 2011

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.